Health Care & Life Sciences » Biotechnology | Charles River Laboratories International Inc.

Charles River Laboratories International Inc. | Balance Sheet

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
167
179
139
122
193
197
Total Accounts Receivable
221
258
270
364
430
472
Inventories
89
89
94
96
115
128
Other Current Assets
75
81
57
75
89
101
Total Current Assets
553
607
559
657
827
898
Net Property, Plant & Equipment
676
677
678
756
782
933
Total Investments and Advances
44
27
34
47
73
90
Intangible Assets
315
500
720
1,182
1,175
1,858
Other Assets
21
51
37
41
51
54
Total Assets
1,645
1,885
2,068
2,712
2,930
3,856
ST Debt & Current Portion LT Debt
21
32
17
27
31
Accounts Payable
32
34
37
68
78
Income Tax Payable
21
11
12
26
43
Other Current Liabilities
173
220
246
308
311
Total Current Liabilities
247
296
312
430
464
Long-Term Debt
642
746
846
1,208
1,114
Provision for Risks & Charges
45
78
65
90
113
Deferred Taxes
21
8
8
27
67
Other Liabilities
31
30
32
75
85
Total Liabilities
980
1,181
1,303
1,858
1,866
Common Equity (Total)
641
672
733
837
1,045
Total Shareholders' Equity
641
672
733
837
1,045
Total Equity
665
704
766
854
1,064
Liabilities & Shareholders' Equity
1,645
1,885
2,068
2,712
2,930
Accumulated Minority Interest
24
32
32
17
19

About Charles River Laboratories International

View Profile
Address
251 Ballardvale Street
Wilmington Massachusetts 01887
United States
Employees -
Website http://www.criver.com
Updated 07/08/2019
Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following business segments: Research Models & Services, Discovery & Safety Assessment, and Manufacturing Support. The Research Models & Services segment comprises of the production and sale of research models, and also offers services designed to support its client's use of research models in screening non-clinical drug candidates.